Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KMT2A rearrange FLT3 exon 14 ins FLT3 D835Y |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KMT2A rearrange FLT3 exon 14 ins FLT3 D835Y | acute myeloid leukemia | sensitive | FHD-286 + Gilteritinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, FHD-286 and Xospata (gilteritinib) synergistically inhibited viability in acute myeloid leukemia cells harboring a KMT2A rearrangement, FLT3-ITD and FLT3 D835Y in culture, and resulted in greater reduction of tumor burden and increased survival compared to either agent alone in a cell line xenograft model (PMID: 40089460). | 40089460 | |
| KMT2A rearrange FLT3 exon 14 ins FLT3 D835Y | acute myeloid leukemia | sensitive | FHD-286 + Quizartinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, FHD-286 and Vanflyta (quizartinib) synergistically inhibited viability in acute myeloid leukemia cells harboring a KMT2A rearrangement, FLT3-ITD, and FLT3 D835Y in culture, and resulted in increased survival compared to treatment with Vanflyta (quizartinib) alone in a cell line xenograft model (PMID: 40089460). | 40089460 |